17 results about "Beta cell" patented technology

The present disclosure relates to a method of generating pancreatic lineage cells, e.g. islet-like cell aggregates comprising pancreatic beta cells, comprising the steps of providing a single cell suspension of a population of endocrine progenitor cells (EP), allowing the EP cells in the single cell suspension to form 3D structures, and culturing the cells under conditions allowing differentiation into pancreatic mono-hormonal beta cells. The present disclosure also relates to islet-like cell aggregates obtainable by said method and their medical use.

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The present disclosure provides a use of a substance targeting BRD4 in the preparation of a product related to diabetes. In the present disclosure, it is found that the expression of BRD4 in human diabetic beta cells is significantly reduced, and BRD4 plays an important role in maintaining beta cell maturation and differentiation, and long-term and acute BRD4 deficiency can lead to reduced insulin secretion and down-regulation of differentiation markers, highlighting the key role of BRD4 in pancreatic beta cells, providing a target BRD4 that has a significant impact on diabetes, so that substances targeting BRD4 can help to assess the susceptibility of diabetes, screening, prevention, intervention and treatment of diabetes.

The application discloses a kind of potential metabolic state modeling gestational diabetes risk assessment and intervention decision method, it is related to medical information technology field, including: first, obtain the minimum metabolic modeling data structure containing individual static information, follow-up observation and intervention data;Second, initialize the latent metabolic state vector formed by insulin sensitivity, beta cell compensatory capacity, fat burden and other latent variables;Then, an observation mapping and state updating mechanism is established, and the state vector is dynamically corrected and updated using follow-up observation and intervention data;Subsequently, based on the updated vector, a metabolic system stability index is calculated to assess patient risk stratification;Finally, by counterfactual reasoning, the state evolution under different hypothetical intervention scenarios is simulated, and the intervention priority and recommendations are output.The present application realizes early identification and precise intervention of risk through microscopic modeling and deduction of latent metabolic state, significantly improving the effectiveness of perinatal and postpartum health management.

This invention discloses the application of adenosine deaminase or its modified forms in the preparation of therapeutic drugs that improve pancreatic islet inflammation and protect pancreatic β-cell function in diabetic patients. This invention is the first to discover that exogenous ADA, through a systemic clearance-local decompression mechanism, enhances circulating ADO clearance, reduces tissue ADO load, restores compensatoryly elevated tissue ADA activity to normal, significantly reduces macrophage infiltration in the islets, inhibits inflammatory factor expression, promotes β-cell proliferation and functional recovery, and improves glucose and lipid metabolism. This invention provides a disease-modifying therapy for diabetes that can simultaneously regulate immunity and metabolism, possessing extremely high clinical application value.

The application provides application of ceramide hydrolase ACER2 in preparation of a medicine for improving beta cell function, preventing and / or treating diabetes. The application proves, for the first time, through a pancreatic islet beta cell damage regeneration model and a diabetes mouse model, that ACER2 is indispensable for regulating ceramide level, improving beta cell function and diabetes pathological phenotype by specifically knocking out a metabolic enzyme ACER2 of vascular endothelial cells; and constructs extracellular vesicles overexpressing ACER2, and proves that the extracellular vesicles overexpressing ACER2 have certain application prospect in improvement of pancreatic islet beta cell function and treatment of diabetes.

Disclosed herein are methods of treating or preventing a metabolic disease in a subject. The methods include administering to the subject a composition comprising Candida dubliniensis in an amount effective to treat or prevent or reduce a metabolic disease. Methods of treating diabetes or promoting or enhancing proliferation of beta cell development or beta cell regeneration are also provided.

The application belongs to the technical field of biological medicine, and particularly relates to application of beta cell protein in preparation of medicines for preventing and treating abortion. The application finds and proves for the first time that the application of beta cell protein (BTC) promotes invasion and tube formation of the extravillous trophoblast cell line-HTR8 cells, BTC has obvious rescue effect on embryo resorption in a mouse model of early-mid pregnancy abortion, and BTC increases placental weight and improves placental development when injected into the mouse model of early-mid pregnancy abortion, thereby indicating that BTC can have certain therapeutic effect on abortion, and thus has good practical application value.

Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and / or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

The application relates to the technical field of biological pharmacy, in particular to application of recombinant protein DEL-1 in preparation of a drug for improving insulin secretion function of human islets. The application finds that the recombinant protein DEL-1 has a significant improvement effect on insulin secretion dysfunction in various human islet injury models. Experiments show that in a high-sugar combined palmitic acid injury model and an inflammatory cytokine injury model, DEL-1 can significantly improve the insulin secretion function of human islets. Specifically, compared with an injury group, after DEL-1 treatment, the glucose stimulation index of human islets and the relative secretion amount of insulin under high-sugar stimulation are both significantly increased, which proves that DEL-1 has a clear effect of promoting insulin secretion function of human islet beta cells.

The invention relates to a diagnostic kit and methods for detecting and quantifying autoantibodies associated with the onset of type 1 diabetes (T1D). The kit comprises recombinant antigen molecules fused to bioluminescent reporter proteins for the detection of autoantibodies directed against self-antigens expressed by pancreatic islet beta cells. The presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The application discloses application of MST1 interfering RNA in promoting in-vitro differentiation of ESCs into insulin-secreting cells, and belongs to the technical field of biotechnology. In the process of in-vitro directional differentiation of rat ESCs into beta cells, the application infects by using an MST1 shRNA lentivirus vector, and indexes are detected and functions are determined by using cell biology and molecular biology methods, and it is found for the first time that the efficiency of inducing ESCs to differentiate into beta cell-like cells can be improved by reducing the expression of MST1. Meanwhile, how MST1 realizes the regulation of beta cell maturation by means of PDX1 in the process of directional differentiation of rat ESCs into beta cells is described, the reason affecting in-vitro maturation of beta cells is discussed, and thus the system of directional differentiation of ESCs into mature beta cells is optimized, which has important significance for obtaining beta cells with normal insulin secretion function in-vitro.

The application discloses an injectable hydrogel of islet-like spheroids based on double sequential encapsulation and a preparation and application thereof, and belongs to the technical field of bioengineering medical materials. The preparation method utilizes the positive and negative charges of a polymer material, forms an immune protection film of islet beta cells through electrostatic adsorption layer-by-layer self-assembly, and utilizes the extracellular matrix of a spleen, i.e., the characteristics of a liquid state in vitro and self-assembly into a nanofiber gel structure at a physiological temperature in vivo, to prepare the injectable hydrogel of islet-like spheroids, so as to ensure the stability of the hydrogel structure, self-assembly into a nanofiber three-dimensional gel structure in vivo, provide a natural specific microenvironment for cell self-renewal and differentiation, promote the aggregation of beta cells into islet-like spheroids, and enhance the insulin secretion and vascularization capacity. The immune protection film is formed on the surface of the islet beta cells through layer-by-layer self-assembly of gelatin and alginate, so that the beta cell immune protection encapsulation is realized.

The application discloses application of a piRNA-145836 preparation in preparation of a medicine for preventing and treating type 2 diabetes induced by high homocysteine, and belongs to the technical field of biological medicine and molecular biology. The nucleotide sequence of the piRNA-145836 is shown as SEQ ID No. 1. The piRNA-145836 can play a key role in type 2 diabetes induced by high homocysteine, and can regulate a mechanism, promote recovery of pancreatic function, restore insulin secretion capacity, reduce abnormal activation of copper death-related proteins, reduce accumulation of copper ions in islet beta cells, and improve sugar metabolism disorder induced by high homocysteine. The application solves the technical problems of lack of cognition of the role of piRNA in copper ion homeostasis and beta cell fate determination, ambiguity of the role target of resveratrol, and unknown expression regulation mechanism of key copper transport proteins in a high homocysteine environment in the prior art.

The present disclosure provides novel methods for increasing β-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase β-cell viability.

Disclosed herein are compositions and methods of enhancing stem cell differentiation into beta cells with use of one or more epigenetic modification compounds. The present disclosure also relates to compositions and methods of sorting and enriching the differentiated beta cells. The present disclosure also relates to compositions and methods of irradiating cell population for reducing proliferation.

The present application relates to the technical field of biological medicine, and particularly relates to a composition taking GLP-1 receptor as a target point, which comprises the following raw materials in parts by weight: gentiana scabra extract 10-25 parts, andrographolide sulfonate 5-15 parts, peganum harmala alkaloid 3-7 parts, curcumin functional compound 20-40 parts, and excipients; the excipients comprise sodium caprate 4-8 parts and konjac glucomannan 8-15 parts. The composition of the present application realizes the ordered synergistic effect in time and space through the triple mechanism of "promoting endogenous GLP-1 secretion at the intestinal end, directly activating GLP-1R at the receptor end and prolonging the half-life, and promoting beta cell regeneration and protection at the effector organ end", reshapes the steady-state regulation ability of the body's own GLP-1 signal axis, improves sugar metabolism, and is suitable for the prevention and treatment of diabetes, obesity and related metabolic diseases.